Literature DB >> 27448990

Effect of a genetically engineered bacteriophage on Enterococcus faecalis biofilms.

Justine Monnerat Tinoco1, Bettina Buttaro2, Hongming Zhang3, Nadia Liss3, Luciana Sassone4, Roy Stevens3.   

Abstract

OBJECTIVE: Enterococcus faecalis is a Gram-positive, facultative anaerobic bacterium that is associated with failed endodontic cases and nosocomial infections. E. faecalis can form biofilms, penetrate dentinal tubules and survive in root canals with scarce nutritional supplies. These properties can make E. faecalis resistant to conventional endodontic disinfection therapy. Furthermore, treatment may be complicated by the fact that many E. faecalis strains are resistant to antibiotics. A potential alternative to antibiotic therapy is phage therapy. ϕEf11 is a temperate phage that infects strains of E. faecalis. It was previously sequenced and genetically engineered to modify its properties in order to render it useful as a therapeutic agent in phage therapy. In the current study, we have further genetically modified the phage to create phage ϕEf11/ϕFL1C(Δ36)PnisA. The aim of this study was to evaluate the efficacy of bacteriophage ϕEf11/ϕFL1C(Δ36)PnisA, to disrupt biofilms of two Enterococcus faecalis strains: JH2-2 (vancomycin-sensitive) and V583 (vancomycin-resistant).
METHODS: 24h static biofilms of E. faecalis strains JH2-2(pMSP3535 nisR/K) and V583 (pMSP3535nisR/K), formed on cover slips, were inoculated with bacteriophage ϕEf11/ϕFL1C(Δ36)PnisA. After 24 and 48h incubation, the bacterial biomass was imaged by confocal microscopy and viable cells were quantified by colony forming unit measurement.
RESULTS: The results showed a 10-100-fold decrease in viable cells (CFU/biofilm) after phage treatment, which was consistent with comparisons of treated and untreated biofilm images visualized as max projections of the Z-series.
CONCLUSION: The biomass of both vancomycin-sensitive and vancomycin-resistant E. faecalis biofilms is markedly reduced following infection by bacteriophage ϕEf11/ϕFL1C(Δ36)PnisA.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antimicrobial; Bacteriophage therapy; Biofilm; Enterococcus faecalis; Public health; Resistance

Mesh:

Year:  2016        PMID: 27448990      PMCID: PMC5048528          DOI: 10.1016/j.archoralbio.2016.07.001

Source DB:  PubMed          Journal:  Arch Oral Biol        ISSN: 0003-9969            Impact factor:   2.633


  50 in total

1.  Biofilms and apical periodontitis: study of prevalence and association with clinical and histopathologic findings.

Authors:  Domenico Ricucci; José F Siqueira
Journal:  J Endod       Date:  2010-06-14       Impact factor: 4.171

2.  Extracellular dextran and DNA affect the formation of Enterococcus faecalis biofilms and their susceptibility to 2% chlorhexidine.

Authors:  Weilan Li; Hongyan Liu; Qiong Xu
Journal:  J Endod       Date:  2012-05-18       Impact factor: 4.171

3.  Enterococcus faecalis--a mechanism for its role in endodontic failure.

Authors:  R M Love
Journal:  Int Endod J       Date:  2001-07       Impact factor: 5.264

Review 4.  Vancomycin-resistant enterococci: clinical, microbiologic, and epidemiologic features.

Authors:  G A Noskin
Journal:  J Lab Clin Med       Date:  1997-07

5.  pH required to kill Enterococcus faecalis in vitro.

Authors:  Christopher P McHugh; Ping Zhang; Suzanne Michalek; Paul D Eleazer
Journal:  J Endod       Date:  2004-04       Impact factor: 4.171

6.  Autoregulation of nisin biosynthesis in Lactococcus lactis by signal transduction.

Authors:  O P Kuipers; M M Beerthuyzen; P G de Ruyter; E J Luesink; W M de Vos
Journal:  J Biol Chem       Date:  1995-11-10       Impact factor: 5.157

7.  In vitro antimicrobial effect of bacteriophages on human dentin infected with Enterococcus faecalis ATCC 29212.

Authors:  A F Paisano; B Spira; S Cai; A C Bombana
Journal:  Oral Microbiol Immunol       Date:  2004-10

8.  Bacteriophages induced from lysogenic root canal isolates of Enterococcus faecalis.

Authors:  R H Stevens; O D Porras; A L Delisle
Journal:  Oral Microbiol Immunol       Date:  2009-08

Review 9.  What happened to the streptococci: overview of taxonomic and nomenclature changes.

Authors:  Richard Facklam
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

10.  Genetic modifications to temperate Enterococcus faecalis phage Ef11 that abolish the establishment of lysogeny and sensitivity to repressor, and increase host range and productivity of lytic infection.

Authors:  H Zhang; D E Fouts; J DePew; R H Stevens
Journal:  Microbiology (Reading)       Date:  2013-04-11       Impact factor: 2.777

View more
  16 in total

1.  Enterococcus phage Nonaheksakonda infecting clinical isolates of Enterococcus faecalis represents a new lineage in the family Siphoviridae.

Authors:  Nikoline S Olsen; Katrine Johansen Nielsen; Maja Plöger; Witold Kot; Lars Hestbjerg Hansen
Journal:  Arch Virol       Date:  2021-01-03       Impact factor: 2.574

2.  Bacteriophage φEf11 ORF28 Endolysin, a Multifunctional Lytic Enzyme with Properties Distinct from All Other Identified Enterococcus faecalis Phage Endolysins.

Authors:  Hongming Zhang; Roy H Stevens; Bettina A Buttaro; Derrick E Fouts; Salar Sanjari; Bradley S Evans
Journal:  Appl Environ Microbiol       Date:  2019-06-17       Impact factor: 4.792

Review 3.  Phages for Biofilm Removal.

Authors:  Celia Ferriol-González; Pilar Domingo-Calap
Journal:  Antibiotics (Basel)       Date:  2020-05-21

4.  Efficacy and safety assessment of two enterococci phages in an in vitro biofilm wound model.

Authors:  Luís D R Melo; R Ferreira; Ana R Costa; H Oliveira; J Azeredo
Journal:  Sci Rep       Date:  2019-04-30       Impact factor: 4.379

5.  Isolation of a Novel Phage and Targeting Biofilms of Drug-Resistant Oral Enterococci.

Authors:  Sonia Bhonchal Bhardwaj; Manjula Mehta; Shaveta Sood; Jyoti Sharma
Journal:  J Glob Infect Dis       Date:  2020-02-19

Review 6.  Overcoming Challenges to Make Bacteriophage Therapy Standard Clinical Treatment Practice for Cystic Fibrosis.

Authors:  Renee N Ng; Anna S Tai; Barbara J Chang; Stephen M Stick; Anthony Kicic
Journal:  Front Microbiol       Date:  2021-01-11       Impact factor: 5.640

7.  Engineered Bacteriophage Therapeutics: Rationale, Challenges and Future.

Authors:  Małgorzata Łobocka; Krystyna Dąbrowska; Andrzej Górski
Journal:  BioDrugs       Date:  2021-04-21       Impact factor: 5.807

Review 8.  Phage therapy as a revolutionary medicine against Gram-positive bacterial infections.

Authors:  Archana Loganathan; Prasanth Manohar; Kandasamy Eniyan; C S VinodKumar; Sebastian Leptihn; Ramesh Nachimuthu
Journal:  Beni Suef Univ J Basic Appl Sci       Date:  2021-08-28

9.  In Vivo Targeting of Clostridioides difficile Using Phage-Delivered CRISPR-Cas3 Antimicrobials.

Authors:  Kurt Selle; Joshua R Fletcher; Hannah Tuson; Daniel S Schmitt; Lana McMillan; Gowrinarayani S Vridhambal; Alissa J Rivera; Stephanie A Montgomery; Louis-Charles Fortier; Rodolphe Barrangou; Casey M Theriot; David G Ousterout
Journal:  mBio       Date:  2020-03-10       Impact factor: 7.867

Review 10.  Emerging Strategies to Combat β-Lactamase Producing ESKAPE Pathogens.

Authors:  Corneliu Ovidiu Vrancianu; Irina Gheorghe; Elena-Georgiana Dobre; Ilda Czobor Barbu; Roxana Elena Cristian; Marcela Popa; Sang Hee Lee; Carmen Limban; Ilinca Margareta Vlad; Mariana Carmen Chifiriuc
Journal:  Int J Mol Sci       Date:  2020-11-12       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.